[#DIV28SUPER] The NIH-DoD-VA Pain Management Collaboratory Funding Opportunity Announcements (FOAs) Letter of Intent due Feb 3, 2017; applications due March 3, 2017

The NIH-DoD-VA Pain Management Collaboratory Funding Opportunity Announcements (FOAs) 


The overall goal of this initiative, jointly supported by the NIH, DoD, and VA, is to develop the capacity to implement cost-effective large-scale clinical research in military and veteran health care delivery organizations focusing on non-pharmacological approaches to pain management and other comorbid conditions.  The NIH-DoD-VA Pain Management Collaboratory Program, will:

  • establish a Coordinating Center to provide leadership and technical expertise in all aspects of research supporting the design and execution of high impact demonstration projects on non-pharmacological approaches for pain management and other comorbid conditions;
  • support the design and execution of a set of high-impact Demonstration Projects that will conduct pragmatic clinical trials on non-pharmacological approaches to pain management and comorbidities with patients in health care delivery systems that provide care to military personnel, veterans and their families;
  • make data, tools, best practices, and resources from these and other projects available to facilitate a research partnership with health care delivery systems that provide care to military personnel, veterans and their families


This funding initiative includes two funding announcements:

  • RFA-AT-17-002: NIH-DoD-VA Pain Management Collaboratory-Coordinating Center (U24), which can be found at the following url: https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-17-002.html   The purpose of this FOA is to solicit applications for a Coordinating Center (CC) to provide national leadership for the NIH-DoD-VA Pain Management Collaboratory program on non-pharmacological approaches to pain management and comorbidities in U.S. military personnel, veterans and their families


  • RFA-AT-17-001:  NIH-DoD-VA Pain Management Collaboratory-Pragmatic Clinical Trials Demonstration Projects (UG3/UH3), which can be found at the following url: https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-17-001.html   The purpose of this FOA is to solicit UG3/UH3 phased cooperative agreement research applications to conduct efficient, large-scale pragmatic clinical trial Demonstration Projects within the NIH-DoD-VA Pain Management Collaboratory on non-pharmacological approaches to pain management and other co-morbid conditions in U.S. military personnel, veterans and their families.  Studies need to be conducted within healthcare systems that serve military, veterans and their families.


Letters of intent are due February 3, 2017; applications are due March 3, 2017.



The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov     301-435-1309




NIH Postdoctoral Research Fellowship Opportunity


The University of Vermont’s Center on Behavior and Health (VCBH) announces NIH postdoctoral research fellowship opportunities in our internationally recognized center of excellence for the study of substance abuse. 

Eligibility: Applicants must have completed their training in psychology, behavior analysis, or a related discipline and be U.S. citizens or permanent residents. Trainees are selected on the basis of scholastic record and commitment to a career in substance abuse research. Individuals must be highly motivated, possess initiative and a desire to learn and expand their interests and expertise.


 Appointment:  2-3 yrs.


 Benefits: Stipend, medical insurance coverage, and travel funds supported by NIH Institutional Training Awards.


To apply: Send application form (downloaded from VCBH website), a cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to:  Dr. Stephen Higgins c/o Ms. Marissa Wells (mwells2@uvm.edu).


About us: The VCBH was established in 2013, sponsored in part by a Centers of Biomedical Research Excellence (COBRE) Award from the National Institute on General Medical Sciences and a Centers of Tobacco Regulatory Science (TCORS) Award from the National Institute on Drug Abuse. The VCBH resides within the College of Medicine at the University of Vermont, with the director and administrative offices being located within the Department of Psychiatry, and participating investigators, collaborators, and advisors across 15 academic departments in the College of Medicine and 7 colleges within the University of Vermont and 5 other universities. The VCBH is further strengthened by interdisciplinary collaborations with key community healthcare leaders and distinguished scientific advisory panels. The focus of the VCBH is on investigating relationships between personal behaviors and risk for chronic disease and premature death, with a specific focus on understanding mechanisms underpinning risk, and developing effective interventions and policies to promote healthy behavior.


 For more information:  Contact Ms. Marissa Wells at mwells2@uvm.edu or see our website.



 Burlington, Vermont is located in the beautiful Lake Champlain region, surrounded by the Green and Adirondack Mountains. It is a great place for families, boasting excellent schools and year-round recreational opportunities. It is home to the University of Vermont and many other colleges that provide an academically stimulating and culturally rich environment. Montreal and Boston are within easy driving distances.


Stephen T. Higgins, Ph.D.
Director, Vermont Center on Behavior and Health
Virginia H. Donaldson Professor of Translational Science
Departments of Psychiatry and Psychology
Vice Chair, Department of Psychiatry
University of Vermont
1 South Prospect Street
Burlington, VT  05401-1419

VCBH Administrator: Marissa Wells


[#DIV28SUPER] FW: HBO/NIAAA Documentary "Risky Drinking" - Premiering Monday, December 19

Dear Colleagues,


The HBO/NIAAA documentary “Risky Drinking”  premieres Monday, Dec. 19 at 8 p.m. ET on HBO.  NIAAA is proud to have collaborated with HBO on this documentary, which examines the lives of four people whose drinking has profoundly impacted their relationships and their lives.  If you subscribe to HBO, please watch it if you’re able. 


This is a compelling film on an important public health topic – Alcohol Use Disorder (AUD).  For more information about the film, additional resources, and information about how to view the film on other HBO platforms, please visit www.hbo.com or www.niaaa.nih.gov/HBO.


About 70% of American adults drink alcohol and, of those, nearly 1/3 will engage in problem drinking at some point in their lives.  The drinking patterns of the individuals profiled in this documentary represent different stages along the AUD spectrum, and their personal stories are gripping and informative.


Here is HBO’s description of the documentary:


Produced by HBO Documentary Films and The National Institute of Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health, Risky Drinking is a no-holds-barred look at a national epidemic through the intimate stories of four people whose drinking dramatically affects their relationships.


Through immersive storytelling, expert commentary and animation, this 85-minute film offers a new perspective on alcohol use and misuse as it falls along a broad spectrum of risk and includes life-saving information about how to help people dial back or stop their drinking. The film aims to provoke a much-needed conversation about how to identify risky drinking and to suggest alternatives to a one-size-fits-all approach that prevents many people from seeking help. 


As we all wish for the health and safety of our loved ones during the holiday season, I hope you will be able to watch this important and informative program.



George F. Koob, Ph.D.



[#DIV28SUPER] Statistician position at Medical University of South Carolina

The Charleston Alcohol Research Center (ARC), within the Addiction Sciences Division (ASD) of the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina (MUSC), is recruiting an Assistant Professor biostatistician to support its research efforts and those of others in the ASD.  The successful applicant for this position will have a PhD degree in quantitative psychology, biometry, statistics or related discipline, and will provide statistical analyses, experimental design, database management and quality control support for research related to alcoholism and other addictive substances. The salary will be commensurate with the selected individual’s experience and potential.  Our goal is to have the selected candidate on-site no later than the summer of 2017.


The ARC, a P50 Center Grant funded by NIAAA, has been in existence for 21 years and forms the backbone for alcohol research within the division. The ARC has 17 affiliated faculty (both clinical and basic science) and many of its faculty are widely recognized leaders in alcohol research. The greater ASD has 34 funded faculty and currently has 14 million dollars of extramural research funding. The ARC is housed within the Institute of Psychiatry, a free standing clinical and research facility on the MUSC Campus.  To learn more about the Charleston Alcohol Research Center and the Addiction Sciences Division, please go to www.musc.edu/arc and www.musc.edu/psychiatry/addiction-sciences.


The ARC is located in historic Charleston, South Carolina, which has been recognized by top travel and leisure magazines as one of the best places in the United States to visit and live. It has a temperate climate and, being one of the oldest cities in the U.S., has numerous historical/cultural sites. It hosts many recurring cultural events including the Spoleto Festival- an internationally recognized performing arts event. It has numerous beaches, golf courses, tennis facilities, riding trails, and is in close proximity to the mountains of North Carolina.


Interested individuals desiring more information should contact Raymond F. Anton, MD by email at antonr@musc.edu or apply directly by going to www.musc.edu/hr and selecting the Search Jobs field.  Under Job Search, enter 497493 and then select the Apply Now button to begin your application.


MUSC is an equal opportunity employer and makes employment decisions without regard to age, race, gender, gender identity, or protected veteran status.






Katie Witkiewitz, PhD

President, Society of Addiction Psychology (APA Division 50)

Associate Professor

Department of Psychology

Center on Alcoholism, Substance Abuse, and Addictions


University of New Mexico

Albuquerque NM 87131

Office phone: 505-277-5953

Vmail: 505-295-2334

Fax: 505-277-1394




[#DIV28SUPER] Time for APA Division 28 award nominations!

As 2016 winds down, please take a moment and consider nominating a colleague, mentor or student for one of our three 2017 APA Division 28 Awards: 

Med Associates Brady-Schuster Award

Young Psychopharmacologist Award

Outstanding Dissertation Award

These awards are an excellent way to honor colleagues in our field. 

Please send your nomination to Cathy Stanger (Catherine.stanger@dartmouth.edu) by January 15, 2017


Listing of awards and grants sponsored by the Division of Psychopharmacology and Substance Abuse (Division 28) for contributions to psychopharmacology.

2016 President, APA Division 28

Stacey Sigmon, Ph.D.
Department of Psychiatry
College of Medicine

University of Vermont
UHC-SATC, Room 1415
1 S. Prospect Street
Burlington, VT 05401
P: (802) 656-9987
F: (802) 656-5793
E: stacey.sigmon@uvm.edu


[#DIV28SUPER] Experimental and Clinical Psychopharmacology

Dear Colleagues-
I am writing to you in my role as the incoming editor for APA's Experimental and Clinical Psychopharmacology. I have identified your division as one that may have an interest in the journal's content. I have appended the updated scope for the journal below, but would like to draw your attention to the new submission types that we will be accepting at the journal: brief communications (no more than 3000 words, excluding references; no more than 2 total figures or tables), case reports (no more than 2000 words; only 1 figure or table) and brief reviews (no more than 5000 words, excluding references). The journal will continue to accept original research reports (no word limit, but should typically be 4-8000 words, excluding references) and full reviews (no word limit).
I hope you will consider submitting relevant manuscripts to the journal and that you will share this information with any potentially interested colleagues.
Please feel free to contact me directly at william.stoops@uky.ed if you have questions about Experimental and Clinical Psychopharmacology.
Thank you,
Bill Stoops.

Journal Scope

Experimental and Clinical Psychopharmacology




Experimental and Clinical Psychopharmacology ® publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse. The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, biochemistry, brain imaging, genetics, medicine, neuroendocrinology, neuroscience, and pharmacology. The overall goal of Experimental and Clinical Psychopharmacology is to provide a forum for high-quality, innovative preclinical and clinical research that advances our understanding of the behavioral and biological determinants of the effects of centrally acting drugs.


The journal publishes original reports and brief communications on the development and evaluation of pharmacotherapies for a range of mental health diagnoses, the influence of genetics and hormones on responses psychoactive drugs, the pharmacological management of pain, and brain imaging studies of the neural correlates of psychoactive drug effects.


 Rigorous preclinical and human laboratory studies,   as well as  controlled clinical trials of novel interventions, relevant to psychopharmacology and/or substance abuse, are particularly encouraged. The journal recommends that all submissions consider relevant biological variables (e.g., age, animal strain, sex) that may influence outcomes in study design and statistical analyses.


When appropriate (e.g., to provide initial clinical documentation of an emerging issue or topic in psychopharmacology and/or substance abuse), the journal will publish case reports. Case reports are expected to be thoughtful and thorough with attention paid to underlying etiology, behavioral, clinical, and laboratory findings. Any hypotheses should be supported by data and extant literature.


The journal will also include  integrative reviews, both full and brief, of advances in research on psychopharmacology and/or substance abuse. Full reviews should provide a broad perspective on a particular area of research or trace the development of critical concepts and experimental approaches. Brief reviews should provide a scholarly perspective on a circumscribed topic or a novel area that has a relatively small number of relevant research studies to consider. It is recommended that authors contact the editor prior to review preparation regarding suitability for the journal.


Each year, the journal will recognize individuals who are recipients of awards from APA Division 28 (Psychopharmacology and Substance Abuse).  Awardees will be invited to submit a full or brief review paper based on their award-winning research contributions.

William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684

Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.